Related Experiment Video
Updated: May 22, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Neonatal neuroblastoma needs the aggressive treatment?
So-Hyun Nam1, Dae Yeon Kim, Seong Chul Kim
1Department of Pediatric Surgery, Inje University Haeundae Paik Hospital, Busan, Korea. namsh@paik.ac.kr
World Journal of Surgery
|May 2, 2012
Summary
Neonatal neuroblastoma (NB) survival is high at 88.2%, despite frequent advanced stages and MYCN amplification. Early intervention for larger tumors may improve outcomes in these rare infant cancers.
Area of Science:
- Pediatric Oncology
- Cancer Genomics
- Neonatal Care
Background:
- Antenatal ultrasound increasingly detects neonatal neuroblastoma (NB).
- Neonatal NB is a rare but aggressive pediatric malignancy.
- Understanding treatment outcomes is crucial for improving survival rates.
Purpose of the Study:
- To review the clinical presentation and treatment outcomes of neonatal neuroblastoma.
- To identify factors influencing survival in infants diagnosed with NB.
Main Methods:
- Retrospective review of 17 pathologically confirmed neonatal NB cases (1999-2010).
- Analysis of patient demographics, tumor characteristics, staging, risk stratification, and MYCN amplification status.
- Evaluation of treatment response and survival data.
Main Results:
- 16% of total NB cases in children were neonatal; 88.2% survival rate observed.
- Common presentations included abdominal mass, distension, tachypnea, and jaundice.
- High rates of advanced stage (4/4S) and MYCN amplification were noted, particularly in non-survivors.
Conclusions:
- Neonatal NB has an 88.2% overall survival rate, but advanced stages and MYCN amplification are prevalent.
- Early treatment for neonatal NB larger than 3 cm is suggested.
- Aggressive management strategies may lead to more favorable outcomes.
